Dietary approaches to improve asthma control
Official title: Individualized Nutrition to Help Asthmatics Improve Lung Function and Energetics (INHALE)
Run by Pennington Biomedical Research Center · NCT06151405 · Data updated 2026-11-12
This study is testing whether different diets can help adults with asthma breathe better and manage their symptoms.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Pennington Biomedical Research Center Academic / other |
| Locations | 1 site (Baton Rouge, Louisiana) |
| Status | Recruiting |
| Started | July 17, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | March 1, 2027 |
| Registry record updated | September 19, 2024 |
| Trial ID | NCT06151405 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with partly controlled or uncontrolled asthma and a stable medication regimen.
✕Probably not a fit
Patients with diabetes, significant comorbidities, or those with dietary restrictions incompatible with the study diets may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot trial investigates the impact of three different dietary interventions on asthma control and lung function in adults with asthma. Participants will be randomly assigned to follow a DGA Diet, MCT Diet, or KETO Diet for seven days, with a washout period in between each diet. The study aims to assess changes in asthma control and lung function after each dietary phase, while also exploring factors that may influence dietary response. A total of 15 adults will be recruited for this crossover design trial.
Why it matters
Potential benefit: If successful, this study could provide new dietary strategies to improve asthma management and enhance lung function.
How similar studies have gone: While dietary interventions in asthma management are being explored, this specific crossover approach is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18-65 years * BMI: 18.5 - 29.99 kg/m2 * asthma diagnosed by medical specialist (confirmed in medical history) * partly controlled or uncontrolled asthma by Asthma Control Test score ≤22 * owns a device compatible with ZEPHYRx platform * stable asthma medication use (no change in the past 2 months). Exclusion Criteria: * Diabetes or using diabetes medications that may lower blood glucose levels * point of care fasting blood glucose ≥126 mg/dl or triglycerides ≥400 mg/dl * current smoking or smoking history of greater than 10 pack-years * other significant respiratory or cardiac disease or the presence of clinically important comorbidities, e.g., COPD, renal failure, liver disease; uncontrolled hypertension defined as systolic blood pressure ≥160 mm/Hg, or diastolic blood pressure ≥100 mm/Hg * pregnant or nursing women * food preferences or allergies inconsistent with study diet capabilities * noncompliance with lead-in period requirements.
Where it's running
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States Recruiting
Study contacts
- Principal investigator: Jacob T Mey, PhD, RD — Pennington Biomedical Research Center
- Study coordinator: Jacob T Mey, PhD, RD
- Email: jacob.mey@pbrc.edu
- Phone: 225-763-2644
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)
A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.